Localized Injection-site Toxic Erythema of Chemotherapy: An Under-recognized Acquaintance Revisited

Ríos‐Viñuela, E.; Bernia, E.; Toledo-Pastrana, T.; Requena, Celia; Diago, A.; Serra‐Guillén, C.; Llombart, B.; Traves, Víctor; Nagore, Eduardo; Guillén, C.; Sanmartín, O.

doi:10.2340/00015555-3791

Cited by 3 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, there is no prior published literature reporting TEC or chemical burns secondary to LHRHa. Given the presence of an erythematous plaque accompanied by blistering, however, our patient's lesion was consistent with goserelin-induced TEC [ 14 ].…”

Section: Discussionmentioning

confidence: 68%

“…Chemical burns broadly fall under the categorization of injection site reactions, a cutaneous phenomenon of various chemotherapeutic agents, collectively known as toxic erythema of chemotherapy (TEC) [14]. While the mechanism is not fully understood, the pathophysiology of TEC may involve direct toxic effects on the epidermis and eccrine epithelium as well as the release of granulsyin by natural killer cells [15][16][17].…”

Section: Figure 2: 9x10 CM Area Of Erythema With Small Overlying Flui...mentioning

confidence: 99%

See 1 more Smart Citation

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature

Mahadevan,

Warnecke,

Chiao

et al. 2023

Cureus

View full text Add to dashboard Cite

A chemical burn resulting from luteinizing hormone-releasing hormone agonists (LHRHa) is a rare adverse effect that has not been well-documented in prior literature. In this case report, we report a partial-thickness burn that developed following a single subcutaneous injection of goserelin. To our knowledge, this is the first description of goserelin-induced chemical burn in the literature. The importance of early identification and treatment of LHRHa-associated cutaneous reactions must be highlighted to ensure optimal oncologic management and patient comfort.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Figure 2: 9x10 CM Area Of Erythema With Small Overlying Flui...mentioning

confidence: 99%

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature

Mahadevan,

Warnecke,

Chiao

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…eruptive nevi, serpentine supravenous hyperpigmentation, flagellate or reticulate hyperpigmentation, melanonychia, and post-inflammatory hyperpigmentation (associated with repeated trauma, toxic erythema of chemotherapy, etc.). 6,10,14 Although post-inflammatory hyperpigmentation following a phototoxic reaction induced by chemotherapeutic agents such as 5-FU, tegafur, vinblastine, dacarbazine, and doxorubicin can occur in some cases, 6 localized or more diffuse hyperpigmentation after UVA/UVB exposure can also develop progressively without an initial inflammatory phase. These lesions are most prevalent in areas regularly exposed to UVA and UVB light, notably the dorsal aspect of the hands (Fig.…”

Section: Diffuse or Localized Hyperpigmentationmentioning

confidence: 99%

“…eruptive nevi, serpentine supravenous hyperpigmentation, flagellate or reticulate hyperpigmentation, melanonychia, and post‐inflammatory hyperpigmentation (associated with repeated trauma, toxic erythema of chemotherapy, etc.) 6,10,14 …”

Section: Chemotherapeutic Agentsmentioning

confidence: 99%

Anticancer treatments and photosensitivity

Sibaud

2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Drug‐induced photosensitivity is associated with a wide range of anticancer treatments, including conventional chemotherapeutic agents, targeted anticancer therapies, and immune checkpoint inhibitors. These dermatologic adverse events can have a major impact on the well‐being and quality of life of cancer patients, leading to dose modifications and interruption or discontinuation of anticancer treatments in severe cases. However, the heterogeneous nature of the photosensitive reactions induced by these agents, as well as the common concomitant use of other potentially photosensitizing drugs (antibiotics, voriconazole, nonsteroidal anti‐inflammatory drugs, etc.), can make the diagnosis and, therefore the prevention, of these adverse events particularly challenging. The aim of this review is to describe the most characteristic forms of photosensitivity observed in patients being treated with anticancer treatments, including phototoxicity and photoallergy, and other potentially photo‐induced manifestations such as UV recall, exaggerated sunburn reactions associated with treatment‐related vitiligo, drug‐induced cutaneous lupus erythematosus, and UV‐induced hyperpigmentation. We also discuss the photosensitive reactions recently reported with new‐generation targeted anticancer therapies and immune checkpoint inhibitors and highlight the importance of continued surveillance to identify photosensitizing agents, and of educating patients on the need for preventive UVA/UVB photoprotective measures.

show abstract

Dermatologic complications in transplantation and cellular therapy for acute leukemia

Babakoohi

Ehsan

et al. 2023

Best Practice & Research Clinical Haematology

View full text Add to dashboard Cite

Localized Injection-site Toxic Erythema of Chemotherapy: An Under-recognized Acquaintance Revisited

Cited by 3 publications

References 16 publications

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature

Anticancer treatments and photosensitivity

Dermatologic complications in transplantation and cellular therapy for acute leukemia

Contact Info

Product

Resources

About